Hyperinflammation with COVID-19: The key to patient deterioration?

BackgroundThe potential risk of cytokine storm in patients with coronavirus disease 2019 (Covid-19) has been described1; we write to share our experience treating a 17-year-old male with haemophagocytic lymphohistiocytosis (HLH) secondary to Covid-19 infection.Case reportThis patient presented with cough, sore throat, anorexia and pyrexia. On examination, he had gross cervical lymphadenopathy and palpable splenomegaly. Nose and throat swab for SARS-CoV-2 was positive and blood tests revealed pancytopaenia with very high ferritin, triglyceride and d-dimer levels. The patient’s HScore2 was calculated at 220, suggesting probability of HLH of 93-96%. Considering Russell and colleagues’3 comments about potential harm of corticosteroid use in patients with Covid-19 infection, the patient was commenced on treatment with the selective IL-1 receptor antagonist drug, Anakinra, and a two day course of intravenous immunoglobulin.ResultsThe patient responded rapidly to treatment, becoming apyrexial after 24 hours. His lymph nodes and spleen began to normalise after the first 48 hours, at which time point the ferritin also started to decrease. He was discharged after 11 days feeling fit and well.ConclusionThis case certainly illustrates the importance of hyperinflammation syndromes in Covid-19. It also raises the question – is the severe pneumonitis seen in patients with Covid-19 an immunological phenomenon? We know that the viral load of patients with Covid-19 seems to peak in the early stages of illness4, 5, however patients deteriorate later in the disease course, at around days 10-14. This patient, who had risk factors for deterioration (male, pancytopaenic), did not develop an oxygen requirement and clinically and biochemically improved rapidly on Anakinra with no adverse events. We might suggest Anakinra to the scientific community as a treatment option in Covid-19 infection.